Research Analysts Offer Predictions for MIRM Q1 Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Research analysts at Leerink Partnrs lowered their Q1 2025 earnings per share (EPS) estimates for shares of Mirum Pharmaceuticals in a note issued to investors on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post earnings per share of ($0.51) for the quarter, down from their prior forecast of ($0.36). The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.43) per share. Leerink Partnrs also issued estimates for Mirum Pharmaceuticals’ Q2 2025 earnings at ($0.39) EPS, Q4 2025 earnings at ($0.12) EPS and FY2027 earnings at $0.58 EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, February 26th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.22). The business had revenue of $99.41 million for the quarter, compared to analysts’ expectations of $96.64 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%.

Several other brokerages have also recently commented on MIRM. Robert W. Baird increased their price target on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an “outperform” rating in a research report on Thursday, February 27th. HC Wainwright upped their price objective on Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $58.20.

Mirum Pharmaceuticals Price Performance

Shares of MIRM stock opened at $39.10 on Friday. The firm has a fifty day moving average of $45.23 and a two-hundred day moving average of $43.96. The firm has a market cap of $1.92 billion, a P/E ratio of -19.36 and a beta of 1.00. Mirum Pharmaceuticals has a 1-year low of $23.14 and a 1-year high of $54.23. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15.

Institutional Trading of Mirum Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. Lord Abbett & CO. LLC acquired a new position in Mirum Pharmaceuticals during the 3rd quarter worth $28,913,000. Raymond James Financial Inc. bought a new stake in shares of Mirum Pharmaceuticals during the fourth quarter valued at about $10,611,000. Nuveen Asset Management LLC lifted its holdings in Mirum Pharmaceuticals by 46.7% in the fourth quarter. Nuveen Asset Management LLC now owns 722,155 shares of the company’s stock worth $29,861,000 after purchasing an additional 229,746 shares during the period. D. E. Shaw & Co. Inc. bought a new position in Mirum Pharmaceuticals in the 4th quarter valued at about $6,507,000. Finally, Marshall Wace LLP increased its stake in Mirum Pharmaceuticals by 641.6% during the 4th quarter. Marshall Wace LLP now owns 175,913 shares of the company’s stock valued at $7,274,000 after buying an additional 152,191 shares during the period.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 902 shares of the firm’s stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $47.92, for a total value of $43,223.84. Following the sale, the senior vice president now owns 3,524 shares in the company, valued at approximately $168,870.08. This trade represents a 20.38 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Christopher Peetz sold 6,837 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $47.92, for a total value of $327,629.04. Following the sale, the chief executive officer now directly owns 125,022 shares in the company, valued at approximately $5,991,054.24. This trade represents a 5.19 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 116,473 shares of company stock valued at $5,249,134. Insiders own 22.87% of the company’s stock.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.